and Supplementary Figure S1b . There was a significant increase in the number 2 2 7 of transition groups when DDA data was added from different tissue types (Supplementary 2 2 8 Figure S2A ), while the increase in the number of proteins was relatively less (Supplementary 2 2 9 Figure S2B ). We further investigated the increase of peptide precursors and proteins in two 2 3 0 well sampled tissue type and found that this DPHL library is not yet complete, probably due 2 3 1 to semi-tryptic peptides and missed cleavages due to biological heterogeneity 2 3 2 (Supplementary Figure S2C, S2D) , awaiting for future expansion with more spectral data. 2 3 3
Next, we analyzed the biological content of the DPHL library. To investigate the 2 3 4 biological coverage of this DPHL, we did GO (Gene Ontology) enrichment analysis using R 2 3 5 package clusterProfiler, as shown in Supplementary Figure S3 , demonstrating that our 2 3 6 DPHL covers proteins with diverse molecular functions. 2 3 7
The kinases were next characterized using KinMap [33] , an online tool that links the 2 3 8 biochemical, structural and disease association data of individual kinases to the human 2 3 9 kinome tree. A total of 340 kinases (63.2% out of 538 known protein kinases) identified in 2 4 0 DPHL were plotted in the KinMap tree. As shown in Supplementary Figure S4 , DPHL covers 2 4 1 all the major branches of the kinome tree. More characteristics of the kinases in DPHL are 2 4 2
show in Supplementary Figure S5 . Transcription factors (TFs) are special proteins that bind 2 4 3 target DNA sequence to regulate and control gene transcription. TFs are extremely 2 4 4 important to disease genesis, development and disease progression. We matched our DPHL 2 4 5 library to the 1639 TFs from the Human Transcription Factors database [34] , and found that 2 4 6 the DPHL covers 33.0% of the known TFs (Supplementary Figure S6 ). 2 4 7 2 4 8
Application of the DPHL library to prostate cancer tissue samples 2 4 9
Next we apply the DPHL library to analyze representative clinical sample cohorts. 2 5 0
First, we procured prostate tissue samples from 17 patients, consisting of 8 prostate cancers 2 5 1 (PCa) and 9 cases of benign prostate hyperplasia (BPH) ( Supplementary Table S3 ), and 2 5 2 analyzed them by QE-HF MS operated in DIA mode. The peptides were separated on a 60 2 5 3 min LC gradient. Two additional technical replicates were randomly selected for each patient 2 5 4
group. Twenty-four DIA files were thus acquired, 4,785 protein groups, 4,391 SwissProt 2 5 5 6 / 2 1 proteins and 3,723 proteotypic proteins were identified from 37,581 peptide precursors that 2 5 6
were searched against the DPHL library using the CiRT strategy ( Figure 3A ). Figure 3B 2 5 7
shows that proteins were identified at a high degree of reproducibility across the samples 2 5 8
tested. The SiRT and CiRT strategies achieved comparable performance ( Figure 3C ). T-2 5 9 SNE[35] plots show that PCa and BPH were clearly distinguished by the data analyzed by 2 6 0 both, the CiRT and SiRT strategies ( Figure 3D ). 2 6 1
Of the 3,723 identified proteins, 1,555 (1,451 up, 104 down) showed significant 2 6 2 differential abundance (Benjamini-Hochberg (BH) adjusted p-values <0.05 and intensity fold-2 6 3 change higher than 2 or lower than 0.5) using CiRT compare to 2,109 (1,954 up and 155 2 6 4 down) proteins using SiRT (see Supplementary Table S3E- plays a role in tumor progression and metastasis, and was reported as a serum biomarker 2 7 6
[ [44] [45] [46] . The boxplots and ROC curves of these proteins are shown in Figure 3E . Plasma is widely used in clinical diagnosis for its convenient access. Here we applied 2 8 0 the DIA mass spectrometry and the DPHL resource to analyze the plasma samples from 2 8 1 DLBCL patients. The plasma samples were procured from 19 DLBCL patients and 18 2 8 2 healthy individuals ( Supplementary Table S5 ). Each unfractionated and un-depleted plasma 2 8 3
sample was trypsinized and the resulting peptides were separated on a 20 min LC gradient 2 8 4
and measured by DIA-MS on a QE-HF instrument. A total of 7,333 peptide precursors were 2 8 5
identified by searching the data against the DPHL plasma subset library using the CiRT 2 8 6 strategy with high technical reproducibility (R 2 = 0.96, Figure 4A ). We identified 507 protein 2 8 7 groups and 304 proteotypic proteins. More detailed information per sample was show in 2 8 8
Supplementary Figure S7 . The DLBCL samples were clearly distinguished from the healthy 2 8 9
control samples by t-SNE analysis of the quantified proteome ( Figure 4B ), indicating that our 2 9 0 workflow can distinguish DLBCL patients from healthy individuals based on their plasma 2 9 1 proteomes. 2 9 2
After comparing the DLBCL/healthy (or normal) plasma proteomes using t-test with 2 9 3 same criteria as the prostate cohort, we identified 24 differential proteins (18 up and 6 down, 2 9 4 Supplementary Table S5D ), from which we choose three biomarker candidates ( Figure 4C ) 2 9 5 which were closely associated to DLBCL among these 24 proteins based on literature, 2 9 6
including C-reactive protein (CRP), CD44 and serum amyloid A1 (SAA-1). CRP is an 2 9 7
indicator of the inflammatory response and has prognostic value in various solid tumors, 2 9 8
including DLBCL [47] . The hyaluronic acid receptor CD44 and SAA-1 have been previously 2 9 9
identified as prognostic biomarkers for DLBCL [48] [49] . The boxplots and ROC curves of 3 0 0 these proteins are shown in Figure 4D . Taken together, our workflow can identify potential 3 0 1 prognostic biomarkers of DLBCL. We then validated the candidate biomarkers using PRM, a highly specific and 3 0 5
sensitive analytical method that can systematically and precisely quantify well-defined sets 3 0 6
of peptides in complex samples. The DPHL spectra were used to develop PRM assays 3 0 7
using Skyline [18]. 3 0 8
Validation in prostate samples. To validate the DIA results of the prostrate samples, we 3 0 9
included another independent cohort, thereby increasing the total number of samples to 73 3 1 0 from 57 patients ( Supplementary Table S4 ). The two best flying peptides were selected for 3 1 1 each protein to measure the abundance of FASN, TPP1 and SPON2 ( Figure 5 ). As shown in 3 1 2 Figure 3E and Figure 5 , the PRM well confirmed the DIA results. As a representative 3 1 3 example, the peak areas of protein TPP1 (O14773) across all samples are shown in 3 1 4
Supplementary Figure S8 . 3 1 5
Validation in plasma samples. The putative DLBCL biomarkers P02741 (CRP) and P0DJI8 3 1 6 (SAA1) that were identified from the DIA dataset were selected for PRM validation. Skyline 3 1 7
was used to visualize characteristic peptides for CRP and SAA1. One of the best flying 3 1 8
peptides were selected for CRP and SAA1 to measure the abundance of each protein, 3 1 9
respectively (Supplementary Figure S9 ). The peak groups of the fragment ions were 3 2 0 manually curated. As shown in Figure S9 , both proteins are highly upregulated in DLBCL 3 2 1 patients compared to healthy individuals, confirming the results obtained by DIA ( Figure 4D ). 3 2 2
As an example, the peak areas of peptide ESDTSYVSLK (m/z 564.77) of CRP (P02741) 3 2 3 across all samples are shown in Supplementary Figures S10.
In this study, we have developed an open-source platform consisting of a 3 2 7
computational pipeline to generate spectral libraries for DIA and PRM analyses on Orbitrap 3 2 8
instruments. We also reported a reference spectral library, which can be used to identify and 3 2 9
validate protein biomarkers in clinical samples using DIA-MS. With over 370,000 peptide 3 3 0 precursors and more than 10,000 proteotypic SwissProt proteins, the DPHL library is the 3 3 1 most comprehensive SWATH/DIA library built to date, and allows convenient partitioning into 3 3 2 tissue-and disease-specific sub-libraries. Additionally, the DPHL is specifically designed for 3 3 3
protein measurement of clinical samples including tissues and plasma, while the PHL is 3 3 4 mainly for cell lines and synthetic peptides. Using this approach, we were able to analyze 3 3 5
proteomes of 20 human tissue and 40 plasma proteomes per MS instrument per day. We 3 3 6
will continue to generate additional DDA files from more types of human tumors with the 3 3 7
ambition of incorporating internal and external data to create a comprehensive resource 3 3 8
reflecting tumor heterogeneity that enables biomarker discovery as a mission of the Human 3 3 9
Proteome Organization Cancer HPP project [50] . By appending these results to the DPHL, 3 4 0
we can increase the human proteome coverage. present in the dataset. The details about the samples are described in Supplementary Table  3  5  5 S1a. Ethics approvals for this study were obtained from the Ethics Committee or Institutional 3 5 6
Review Board of each participating institution. 3 5 7
Chinese cancer tissue cohorts 3 5 8
Prostate cancer FFPE samples were acquired from the Second Affiliated Hospital of 3 5 9
Zhejiang University School of Medicine. The first cohort included 3 PCa patients and 3 3 6 0 patients with BPH was used for DPHL library building. The second cohort containing 8 PCa 3 6 1 patients and 9 BPH patients was selected for DIA-MS proteotyping. For each patient, four 3 6 2 tissue biopsies (punch 1×1×5 mm 3 ) from the same region were procured for the subsequent 3 6 3
PCT-SWATH/DIA workflow for targeted quantitative proteomics profiling. Besides the 3 6 4
second cohort, a third cohort included 53 patients (16 BPH and 57 PCa) was also included 3 6 5
for PRM validation. PRM and DIA analyses were performed in technical duplicate. 3 6 6
Information about samples of patient used for DIA and PRM measurements are described in 3 6 7
Supplementary Table S3 and Supplementary Table S4 .
The colorectal tissue cohort (CRC) was acquired from histologically confirmed tumors 3 6 9
at the First Affiliated Hospital of Zhejiang University School of Medicine and the Second 3 7 0
Affiliated Hospital of Zhejiang University School of Medicine. Among the 15 donors, 8 3 7 1 patients were diagnosed with colorectal adenocarcinoma, 1 patient with mucinous 3 7 2 adenocarcinoma, 3 patients with adenoma, 2 patients with polyps and 1 with benign tissue at 3 7 3
the edge of colorectal tumors. FF tissue samples were snap frozen and stored in liquid 3 7 4
nitrogen immediately after surgery and were transported to the proteomics lab within 24h. 3 7 5
The colorectal tissue cohort of 15 donors consisted of FFPE and fresh frozen (FF) tissue 3 7 6
samples. These samples (1.5x1.5x5 mm 3 in size) were punched from pathologically 3 7 7
confirmed tissue area by Manual Tissue Arrayer MTA-1 (Beecher, US). FF tissue samples 3 7 8
were snap frozen and stored in liquid nitrogen immediately after surgery and were 3 7 9
transported to the proteomics lab within 24h. 3 8 0
The hepatocellular carcinoma (HCC) cohort and lung adenocarcinoma cohort were 3 8 1 collected from Union hospital, Tongji Medical College, Huazhong University of Science and 3 8 2
Technology. Sixty-six tissue samples (benign and tumor) from 33 HCC patients were 3 8 3
collected within one hour after hepatectomy, then snap frozen and stored at -80 °C. Sixteen 3 8 4
tissue samples (matched benign and tumor pairs) from 8 lung adenocarcinoma patients 3 8 5
were collected within one hour after pneumonectomy, then snap frozen and stored at -80°C. 3 8 6
The cervical cancer cohort was collected from Tongji Hospital, Tongji Medical 3 8 7
College, Huazhong University of Science and Technology. Thirteen FFPE cancerous and 3 8 8 benign tissues were obtained from patients with operable cervical cancer. 3 8 9
Chinese cancer plasma cohorts 3 9 0
Pooled plasma for building the plasma library was created by mixing plasma (10ul for 3 9 1 each patients) from 20 patients from Union Hospital, Tongji Medical College, Huazhong 3 9 2
University of Science and Technology. Each of the 20 patients had one of the following 3 9 3
hematologic malignancies: acute myelocytic leukemia (AML), acute lymphoblastic leukemia 3 9 4 (ALL), chronic myelocytic leukemia (CML), multiple myeloma (MM), myelodysplastic 3 9 5 syndrome (MDS) and diffuse large B cell lymphoma (DLBCL). The validation cohort 3 9 6
consisted of two groups: 18 clinically healthy volunteers from the Second Affiliated Hospital, 3 9 7
Zhejiang University School of Medicine; and 19 patients diagnosed with DLBCL from Union 3 9 8
Hospital, Tongji Medical College. 3 9 9
Dutch cancer tissue cohorts 4 0 0
The glioblastoma, DLBCL, AML, ALL, cervical, pancreatic and gastric cancer cohorts 4 0 1
were collected at Amsterdam UMC/VU medical center, Amsterdam. mirVana aceton 4 0 2 precipitations of 19 glioblastoma cancer tissues were pooled by EGFR status (10 wild-type 4 0 3 9 / 2 1 EGFR and 9 mutant (vIII) EGFR samples). Similarly, mirVana aceton precipitations of 27 4 0 4
DLBCL lymphoma patients were pooled by origin (12 samples of neck origin and 17 of non-4 0 5 neck origin). For AML, 2 pools of 2 patient samples each were prepared. For ALL, 14 4 0 6
individual primary ALL cell samples were used, 9 glucocorticoid (GC) resistant and 5 GC 4 0 7
sensitive. Cervical cancer tissue lysates of 16 patients were prepared and pooled by subtype 4 0 8
(9 SCC and 7 AdCa samples). For pancreatic cancer, individual tissue lysates of 20 patients 4 0 9
were used. For gastric cancer, tissues in the form of FFPE material of 10 patients were 4 1 0 pooled by tumor percentage (7 with over 50% and 3 with 50% or lower). 4 1 1
The lung cancer cohort was acquired from Amsterdam UMC/VU medical center, 4 1 2
Amsterdam and Antoni van Leeuwenhoek hospital/Netherlands Cancer Institute, Amsterdam. 4 1 3
Tumor resection samples in the form of FFPE material were collected from 10 lung 4 1 4
adenocarcinoma, 10 squamous cell lung carcinoma and 3 large cell lung carcinoma patients 4 1 5
and pooled per subtype. 4 1 6
The soft tissue sarcoma cohort was acquired from Antoni van Leeuwenhoek 4 1 7
hospital/Netherlands Cancer Institute, Amsterdam. 7 sarcoma and 9 sarcoma metastasis 4 1 8
tissues were pooled, respectively. 4 1 9
Prostate and bladder cancer cohorts were acquired from Amsterdam UMC/VU 4 2 0 medical center, Amsterdam and Erasmus University Medical Center, Rotterdam. 18 prostate 4 2 1 cancer tissues and 9 control tissues in the form of FFPE material were pooled, respectively. 4 2 2
In addition, 22 fresh frozen prostate cancer tissues were combined to 2 pools of 11 samples 4 2 3 each. 10 bladder cancer tissues in the form of FFPE material were pooled in 2 pools of 5 4 2 4 samples each. 4 2 5
The CRC and triple-negative breast cancer (TNBC) cohorts were collected at 4 2 6
Erasmus University Medical Center, Rotterdam. For CRC, 2 pools were made per CMS 4 2 7 subtype (CMS1, 2, 3 and 4), whereby each pool contained tissue lysates of 5 patients. For 4 2 8
TNBC, 2 pools of 23 and 24 patient tissues each were used. 4 2 9
Singapore thyroid cancer cohort 4 3 0
The thyroid tissue cohort was kindly provided by National Cancer Centre, Singapore. 4 3 1 105 FFPE thyroid tissue punches from 63 patients were included in this study. The cohort is 4 3 2 composed of 5 patients with normal thyroid, 28 with multinodular goiter, 10 with follicular 4 3 3 thyroid adenoma, 5 with follicular thyroid carcinoma and 15 with papillary thyroid carcinoma. 4 3 4 4 3 5
Pre-treatment and de-crosslinking of FFPE tissue samples 4 3 6
About 1 mg of FFPE tissue was first dewaxed three times by heptane, then 4 3 7 rehydrated in a gradient of 100%, 90%, 75% ethanol. PCT-assisted tissue lysis and digestion 4 4 8
About 1mg of de-crosslinked FFPE tissue or pre-washed FF tissue was mixed with 4 4 9
35µL lysis buffer containing 6M urea and 2M thiourea, 0.1mM NH 4 HCO 3 (pH 8.5) in 4 5 0 microtubes and capped with micropestles (PBI, MA, USA). Alternatively, if the proteins were 4 5 1 1 0 / 2 1 extracted for later 1D SDS-page separation, 1% SDS in Milli-Q water was used instead of 4 5 2 urea/thiourea lysis buffer. Tissues were lysed in a barocycler NEP2320-45k (Pressure 4 5 3
BioSciences Inc.) at the PCT scheme of 30s high pressure at 45kpsi plus 10s ambient 4 5 4 pressure, oscillating for 90 cycles at 30°C. Extracted proteins were reduced and alkylated by 4 5 5
incubating with 10mM Tris(2-carboxyethyl) phosphine (TCEP) and 20mM iodoacetamide 4 5 6 (IAA) at 25 °C for 30 min, in darkness, by gently vortexing at 800 rpm in a thermomixer. 4 5 7
Afterwards, proteins were digested by Lys-C (Hualishi Beijing; enzyme-to-substrate ratio, 4 5 8 1:40) using the PCT scheme of 50 s high pressure at 20 kpsi plus 10 s ambient pressure, 4 5 9
oscillating for 45 cycles at 30°C. This was followed by a tryptic digestion step followed 4 6 0 (Hualishi Beijing; enzyme-to-substrate ratio, 1:50) using the PCT scheme of 50 s high 4 6 1 pressure at 20kpsi plus 10s ambient pressure, oscillating for 90 cycles at 30°C. Finally, 15 4 6 2 µL of 10% trifluoroacetic acid (TFA) was added to each tryptic digest to quench the 4 6 3 enzymatic reaction (final concentration of 1% TFA). Peptides were purified by BioPureSPN 4 6 4
Midi C18 supplemented with 150 mM DTT, and the mixture was boiled at 95°C for 5 min.1D gel 4 9 4 electrophoresis was performed using 4-12% gradient SDS-PAGE after which the gel was 4 9 5
removed, washed first with distilled water and then with the fixing buffer (50% (v/v) ethanol in 4 9 6
water with 5% (v/v) acetic acid) at room temperature for 15 min with gentle agitation to 4 9 7
remove excessive SDS. The fixed and washed gel was stained in Coomassie blue for 4 9 8
around 1 h with gentle agitation, and then de-stained until the background was clear and 4 9 9
protein bands were visible. The gel was rehydrated in distilled water at room temperature for 5 0 0 30 min with gentle agitation. Ten protein bands to cover each lane were cut out and further 5 0 1 cut into ca 1 × 1 mm 2 pieces, followed by reduction with 10 mM TCEP in 25mM NH 4 HCO 3 at 5 0 2
25°C for 1 h, alkylation with 55 mM IAA in 25 mM NH 4 HCO 3 solution at 25°C in the dark for 5 0 3 1 1 / 2 1 30 min, and sequential digestion with trypsin at a concentration of 12.5 ng/mL at 37°C 5 0 4
overnight (1 st digestion for 4hrs and 2 nd digestion for 12hrs). Tryptic-digested peptides from 5 0 5 gel pieces were extracted three times using 50% ACN/5% FA and dried under vacuum. Dry 5 0 6 peptides were purified by Pierce C18 Spin Tips (Thermo Fisher, USA). 5 0 7
Preparation and fractionation of plasma protein samples 5 0 8
Venous blood of each patient was collected in EDTA and anticoagulation proceeded 5 0 9
for 9 hours. Plasma samples obtained by centrifugation were transferred to a new set of 1.5 5 1 0
mL Eppendorf tubes and stored at 4°C. Samples were cold-transported from the hospital to 5 1 1 the proteomics lab within 36 h at 4°C. Samples were centrifuged again at 300g for 5min at 5 1 2 4°C to remove cells and the supernatants were further centrifuged at 2500g for 15min at 4°C 5 1 3
to remove cell debris and platelets. The final supernatants were stored at -80°C for further 5 1 4
protein extraction and in solution digestion. 5 1 5
To remove very high abundant plasma proteins in this study, whole plasma peptides 5 1 6
were further extensively fractionated by several methods such as SDS-PAGE separation, 5 1 7
antibody-depletion of high abundant proteins and exosome isolation. 5 1 8
For SDS-PAGE fractionation, the entire gel was cut into 12 thin gel rows, of which 5 1 9
four rows with heavily stained protein bands (3 adjacent bands between 45-75 kD, and a 5 2 0
band between 25 and 35 kD) were picked out for depletion of high abundant proteins. Each 5 2 1 of the other 8 rows was subjected to in-gel digestion as described above. We also used High 5 2 2
Select Top 14 Abundant Protein Depletion Resin spin columns (Thermo Scientific, A36370) 5 2 3
to deplete high abundance proteins in plasma samples according to the manufacturer's 5 2 4
instructions; and further fractionated and digested the depleted plasma proteins by 1D SDS-5 2 5
PAGE. 5 2 6
To obtain the enriched exosome fraction, an aliquot of 200 µL plasma was taken 5 2 7
after centrifuging venous blood for 10 min at 3000 g, 4°C. The exosome pellet was collected 5 2 8
after ultracentrifugation at 160,000g, 4°C for 12h and resuspended in cold phosphate-5 2 9
buffered saline for washing. Resuspended exosomes were further centrifuged at 100,000g, 5 3 0
4°C for 70 min. The pellet was collected and redissolved in 150 µL of 2% SDS. The 5 3 1 exosome fraction in 2% SDS was subjected to PCT-assisted sample lysis, undergoing 60 5 3 2 cycles at 20°C, with 45 k p.s.i. for 50s and atmosphere pressure for 10 s. After lysis, the 5 3 3 exosome protein mixture was precipitated with 80% cold acetone at -20°C for 3h and the 5 3 4
suspension was centrifuged at 12,500 g, 4°C for 15 min to collect the protein pellet. The 5 3 5
protein pellet was redissolved with 200 µL of 1% SDS, followed by SDS-PAGE separation 5 3 6
and subsequent in-gel digestion. Each exosome protein sample was cut into three fractions 5 3 7
and digested as described above. 5 3 8 5 3 9
Strong cation-exchange (SCX) fractionation at peptide level for building DDA library 5 4 0
The SCX solid phase extraction (SPE) cartridge (Thermo Scientific, # 60108-421) 5 4 1 was conditioned first according to the manufacturer's protocol. For SCX fractionation, about 5 4 2 1mg peptides were dissolved in 1 mL of 5 mM KH 2 PO 4 /25%ACN (pH = 3.0), then the 5 4 3
peptide solution was loaded onto the well-conditioned SCX SPE cartridge. The cartridge was 5 4 4
then rinsed with 5mM KH 2 PO 4 /25%ACN (pH = 3.0). Finally, six peptide fractions were 5 4 5
collected by eluting the cartridge with 1.5 mL increments of increasing KCl concentration in 5 4 6
5mM KH 2 PO 4 /25%ACN, i.e. 50 mM, 100 mM, 150 mM, 250 mM, 350 mM, and 500 mM. 5 4 7
Each fraction was collected and vacuumed to dryness. Dry peptides and precipitated salts 5 4 8
were redissolved in 200µL of 0.1% TFA and subjected to further C18 desalting by 5 4 9
BioPureSPN Midi SPE (Nest Group, Cat # HEM S18V). 5 5 0 5 5 1 DDA data acquisition in Jimenez lab 5 5 2
